Sanofi wins SCOTUS stay of Lantus patent dispute

Pharmaceutical company Sanofi has been granted a stay by the US Supreme Court in its ongoing patent litigation battle with Netherlands-based Mylan over glargine ( Lantus), a treatment for type 2 diabetes.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

PTAB institutes IPRs on Sanofi patents

20 December 2017 The US Patent Trial and Appeal Board has instituted inter partes reviews of two patents owned by Sanofi covering Lantus (insulin glargine injection).

Americas

Fed Circuit won’t revisit Sanofi’s PTAB appeal despite Arthrex

30 January 2020 The US Court of Appeals for the Federal Circuit has thrown out Sanofi’s request to apply the recent Arthrex ruling on the constitutionality of the Patent Trial and Appeal Board to more cases.

More on this story

Americas

PTAB institutes IPRs on Sanofi patents

20 December 2017 The US Patent Trial and Appeal Board has instituted inter partes reviews of two patents owned by Sanofi covering Lantus (insulin glargine injection).

Americas

Fed Circuit won’t revisit Sanofi’s PTAB appeal despite Arthrex

More on this story

Americas

PTAB institutes IPRs on Sanofi patents

20 December 2017 The US Patent Trial and Appeal Board has instituted inter partes reviews of two patents owned by Sanofi covering Lantus (insulin glargine injection).

Americas

Fed Circuit won’t revisit Sanofi’s PTAB appeal despite Arthrex